BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19933691)

  • 1. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
    Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
    J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
    Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
    Liu P; Foster G; Gandelman K; LaBadie RR; Allison MJ; Gutierrez MJ; Sharma A
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3617-26. PubMed ID: 17646413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation.
    Kikuchi T; Mori T; Yamane A; Kato J; Kohashi S; Okamoto S
    Clin Transplant; 2012; 26(5):E544-8. PubMed ID: 23061764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
    Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
    J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Brown J; Freeman BB
    Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
    Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
    Purkins L; Wood N; Kleinermans D; Love ER
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
    Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.
    Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J
    J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing voriconazole in an obese patient.
    Dickmeyer NJ; Kiel PJ
    Clin Infect Dis; 2011 Oct; 53(7):745. PubMed ID: 21846833
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
    Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
    Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
    Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
    Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.